This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.
CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab
by Zacks Equity Research
CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.
CytoDyn Reports Top-Line Data From Phase II Coronavirus Study
by Zacks Equity Research
CytoDyn (CYDY) announces top-line results from a phase II study evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.
CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study
by Zacks Equity Research
CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
CytoDyn's Leronlimab Progressing Well in Coronavirus Program
by Zacks Equity Research
CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.
Calithera (CALA) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
New Strong Sell Stocks for February 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Can CytoDyn (CYDY) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
CytoDyn (CYDY) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.